Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (21-30 of 123) with videos related to

Pageof 13
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 31, 2013
Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug AdministrationRonald D Perrone, Stephen Joel Coons, Kerri Cavanaugh, et al.
Kidney360|November 21, 2023
Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4Joga Gobburu, Vijay Ivaturi, Xiaofeng Wang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney DiseaseDorothee Oberdhan, Jason C Cole, Mark J Atkinson, et al.
Biomaterials|September 4, 2012
The regulation of cystogenesis in a tissue engineered kidney disease system by abnormal matrix interactionsBalajikarthick Subramanian, Wei-Che Ko, Vikas Yadav, et al.
Kidney International Reports|June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKDRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Kidney International Reports|June 11, 2020
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan FormulationsRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Kidney360|November 19, 2024
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence ProgramElise Hoover, Heidi Cambareri, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 3, 2019
Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)Kimberly A Smith, Aliza M Thompson, David A Baron, et al.
American Journal of Nephrology|May 21, 2018
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney DiseaseStephen L Seliger, Kaleab Z Abebe, Kenneth R Hallows, et al.
Kidney International Reports|August 13, 2021
Tolvaptan in ADPKD Patients With Very Low Kidney FunctionVicente E Torres, Ron T Gansevoort, Ronald D Perrone, et al.
Pageof 13

Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 31, 2013
Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug AdministrationRonald D Perrone, Stephen Joel Coons, Kerri Cavanaugh, et al.
Kidney360|November 21, 2023
Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4Joga Gobburu, Vijay Ivaturi, Xiaofeng Wang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney DiseaseDorothee Oberdhan, Jason C Cole, Mark J Atkinson, et al.
Biomaterials|September 4, 2012
The regulation of cystogenesis in a tissue engineered kidney disease system by abnormal matrix interactionsBalajikarthick Subramanian, Wei-Che Ko, Vikas Yadav, et al.
Kidney International Reports|June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKDRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Kidney International Reports|June 11, 2020
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan FormulationsRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Kidney360|November 19, 2024
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence ProgramElise Hoover, Heidi Cambareri, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 3, 2019
Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)Kimberly A Smith, Aliza M Thompson, David A Baron, et al.
American Journal of Nephrology|May 21, 2018
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney DiseaseStephen L Seliger, Kaleab Z Abebe, Kenneth R Hallows, et al.
Kidney International Reports|August 13, 2021
Tolvaptan in ADPKD Patients With Very Low Kidney FunctionVicente E Torres, Ron T Gansevoort, Ronald D Perrone, et al.
Pageof 13